New treatment possibilities in ovarian cancer patients with BRCA1/2 mutations

04/2017

Doc. MUDr. Michal Zikán, Ph.D.

Onkogynekologické centrum, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

 

SUMMARY

A new drug using a unique mechanism of action - an intervention in DNA repair - is being introduced into the treatment of ovarian cancer. Olaparib is a drug of the so-called PARP inhibitor group. Interference with the mechanism of DNA repair is particularly effective in BRCA1/2 gene mutation carriers, in whom one of reparation ways is primarily faulty by a germ-line or somatic mutation. Olaparib in the treatment of platinum-sensitive recurrent ovarian cancer in BRCA1/2 mutation carries leads to prolonged progression-free survival and increased overall survival.

 

KEY WORDS

olaparib, PARP inhibitors, BRCA1, BRCA2, ovarian cancer

 

 

Celý článek je dostupný pouze pro předplatitele

Staňte se pravidelným odběratelem našeho časopisu Onkologická revue...

 

VÍCE O PŘEDPLATNÉM